Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis: Implications for clinical trials

Archives of Neurology

Volumn 46, Issue 10, 1989, Pages 1107-1112

  Goodkin, Donald E ^a   Hertsgaard, Doris ^a   Rudick, Richard A ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

CLINICAL TRIALS; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RESEARCH DESIGN; TIME FACTORS;

EID: 0024431267     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1989.00520460093019     Document Type: Article

References (23)

1. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: A randomized three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308:173-180.
2. Goodkin DE, Plencner S, Palmer-Saxerud J, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis: Maintenance vs nonmaintenance therapy. Arch Neurol. 1987;44:823-827.
3. Muller R. Studies in disseminated sclerosis: with special reference to symptomatology, course, and prognosis. Acta Med Scand. 1949;222:1-214.
4. McAlpine D, Compston N. Some aspects of the natural history of disseminated sclerosis. Q J Med. 1952;21:135-167.
5. McAlpine D, Compston ND, Lumsden CE. Multiple Sclerosis. Edinburgh, Scotland: E&S Livingstone; 1955.
6. McAlpine D. The benign form of multiple sclerosis: A study based on 241 cases seen within three years of onset and followed-up until the tenth year or more of the disease. Brain. 1961;84:186-203.
7. Leibowitz U, Halpern L, Alter M. Clinical studies of multiple sclerosis in Israel, I: A clinical analysis based on a country-wide survey. Arch Neurol. 1964;10:502-512.
8. Thygesen P. Disseminated sclerosis: influence of age on different modes of progression. Acta Psychiatr Neurol Scand. 1955;30:365-374.
9. Hallpike JF, Adams CWM, Tourtellotte WW, eds. Multiple Sclerosis: Pathology, Diagnosis and Management. Baltimore, Md: Williams & Wilkins; 1983.
10. Alexander L, Berkely AW, Alexander AM. Prognosis and treatment of multiple sclerosis: quantitative nosometric study. JAMA. 1958;166:1943-1949.
11. McIntyre HD, McIntyre AP. Prognosis of multiple sclerosis. Arch Neurol Psychiatry. 1943;50:431-438.
12. McAlpine D. Course and diagnosis. In: McAlpine D, Lumsden CE, Acheson ED, eds. Multiple Sclerosis: A Reappraisal. New York, NY: Churchill Livingstone Inc; 1972:chap 7.
13. Bauer HJ, Firnhaber W, Winkler W. Prognostic criteria in multiple sclerosis. Ann NY Acad Sci. 1965;122:542-551.
14. Broman T, Anderson O, Bergmann L. Clinical studies on multiple sclerosis, I: presentation of an incidence material from Gothenburg. Acta Neurol Scand. 1981;63:6-33.
15. Fog T, Flemming I. The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand. 1970;46(suppl 47):1-172.
16. Kurtzke JG. Course of exacerbations of multiple sclerosis in hospitalized patients. Arch Neurol Psychiatry. 1956;76:175-184.
17. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
18. Haber A, LasRocca N, eds. Minimal Record of Disability for Multiple Sclerosis. New York, NY: National Multiple Sclerosis Society; 1985.
19. Papac R. Multiple sclerosis: clinical review. Stanford Med Bull. 1957;15:75-77.
20. Carter S, Sciarra D, Merrit HH. Course of multiple sclerosis as determined by autopsy proven cases. Assoc Res Nerv Ment Dis. 1950;28:471-511.
21. Uhlenbrock D, Seidel D, Gehlken W, et al. MR imaging in multiple sclerosis: comparison with clinical, CSF, and visual evoked potential findings. AJNR. 1988;9:59-67.
22. Gonzalez-Scarano F, Grossman RI, Galetta S. Multiple sclerosis disease activity correlated with gadolinium-enhanced magnetic resonance imaging. Ann Neurol. 1987;21:300-306.
23. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in MS: improved assessment sensitivity with the use of the box and block and nine hole peg tests. Arch Phys Med Rehabil. 1988;69:850-854.